ViroMissile

Website

ViroMissile, Inc.

5 Investors
Biotechnology
LA JOLLA, CA

ViroMissile, Inc. is an innovative biotech company based in California, dedicated to transforming cancer treatment through its groundbreaking IDOV™ (Intravenously Deliverable Oncolytic Virus) platform. Founded in 2018, the company focuses on developing advanced cancer therapies that aim to provide effective, one-time treatments for patients with various cancers, particularly metastatic tumors.

Products & Team

IDOV™ platform

Oncolytic Virus TherapySeed

The IDOV™ platform utilizes genetically engineered vaccinia viruses to selectively target and destroy cancer cells while simultaneously activating the body's immune response. This platform enables the delivery of the treatment via intravenous methods, allowing it to reach tumors throughout the body.

Value Proposition

IDOV™ provides a potential 'one-shot' cure for various cancers, effectively targeting metastatic tumors and offering hope to patients with limited treatment options.

Pain Points

The need for effective cancer therapies that can overcome limitations of current treatments, such as invasive administration and limited efficacy against metastatic tumors.

Intravenous delivery for systemic treatmentSelective infection of cancer cellsEnhancement of immune response against tumors
Industry
Biotechnology
Primary business sector
Founded
2025
Year established
Location
LA JOLLA, CA
Primary headquarters

Funding History

Total Raised:
$500.0K
E

Equity, Security Offering

March 2025
$15.0M
Target
Progress
3%
Raised
$500.0K
Target
$15.0M
#000197479825000003